Hepatocellular Carcinoma (HCC)
Conditions
Keywords
Tyrosine kinase inhibitor, Immune checkpoint inhibitor, Multikinase inhibitors
Brief summary
1. To investigate the efficacy and safety of cabozantinib in patients with progressive HCC after ICI-based combination treatment. 2. To explore potential tissue and peripheral blood biomarkers associated with clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and cabozantinib.
Detailed description
Immune checkpoint inhibitor (ICI)-based combination therapy, such as atezolizumab-bevacizumab or tremelimumab-durvalumab, has become the current standard first-line treatment for advanced hepatocellular carcinoma (HCC). However, there is no approved second-line treatment yet following progression on these ICI-based combination therapies. Multikinase inhibitors (MKIs), such as lenvatinib, sorafenib, cabozantinib, and regorafenib, are often recommended by established guidelines, expert consensus, and retrospective studies. However, this approach lacks robust evidence from prospective studies or reliable biomarkers for patient selection. Cabozantinib, a MKI targeting vascular endothelial growth factor receptor (VEGFR), MET, and the TAM family of kinases (TYRO3, AXL, and MER), is one of the standard post-sorafenib treatments for advanced HCC. It has shown comparable effectiveness to sorafenib in the first-line setting. The safety profile of cabozantinib is well established and manageable. Furthermore, cabozantinib offers several advantages that make it a rational treatment option after ICI failure: 1. Potent VEGFR inhibition: Cabozantinib effectively inhibits angiogenesis, which is essential for tumor growth. 2. Additional AXL inhibition: Cabozantinib targets AXL, which is a key mediator of tumor progression and ICI resistance across different cancer types. 3. Clinical evidence: A recent phase II trial demonstrated that around 30% of patients receiving cabozantinib after progression with ICIs remained progression-free at 6 months, despite an objective response rate of 6%. This underscores the need for biomarkers to identify patients who are more likely to benefit from cabozantinib after ICI failure. In this trial, the investigators aim to investigate the efficacy and safety of cabozantinib in HCC patients who have progressed on first-line ICI-based combination. Additionally, the investigators will explore tumor tissue and peripheral blood biomarkers for clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and current cabozantinib.
Interventions
DRUGCabozantinib
All patients will be treated with cabozantinib at 60 mg once daily.
Sponsors
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan
Tri-Service General Hospital
Mackay Memorial Hospital
Chang Gung Memorial Hospital
China Medical University Hospital
Taichung Veterans General Hospital
National Cheng-Kung University Hospital
National Health Research Institutes, Taiwan
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Understood and signed the informed consent form 2. Ability to comply with all protocol requirements 3. Age ≥ 18 years when signing informed consent form 4. Diagnosis of HCC confirmed by histology 5. Disease progression following prior first-line ICI-based combination therapy (only atezolizumab plus bevacizumab or tremelimumab plus durvalumab is permitted. Any liver-directed locoregional therapies administered during the treatment period of the first-line ICI-based combination therapy are allowed. 6. Disease that is not amenable to curative surgical and/or locoregional therapies (e.g. surgery, transplant, radiofrequency ablation) 7. At least one measurable target lesion (per RECIST v1.1) that has not been previously treated with local therapy (e.g., radiofrequency ablation, cryoablation, transarterial embolization, transaraterial chemoembolization, radiotherapy, etc.) or, if the target lesion is within the field of previous local therapy, has subsequently progressed in accordance with RECIST v1.1. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 9. Child-Pugh A of liver reserve 10. Adequate hematologic and biochemical profiles: * White blood cells (WBC) ≥ 3,000/μL and absolute neutrophil count (ANC) ≥ 1,200/μL without granulocyte colony-stimulating factor support within 1 week before registration * Platelets (PLT) ≥ 60,000/μL without transfusion within 1 week before registration * Hemoglobin (Hb) ≥ 8 g/dL without transfusion within 1 week before registration * Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≥ 40 mL/min (using the Cockroft-Gault equation) * Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) ≤5 × ULN * Serum total bilirubin (T-Bil) ≤ 2× ULN * Serum albumin (Alb) \> 28 g/L (2.8 g/dL) * Urinalysis for proteinuria \< 2+. Patients discovered to have ≥ 2+ proteinuria on urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \< 1 g of protein in 24 hours. 11. Recovery to grade 1 from AEs related to any prior treatments, unless the AEs are clinically nonsignificant and/or stable on supportive therapy 12. Subjects with chronic hepatitis B virus (HBV) infection (defined as HBV surface antigen. positive; HBsAg+) must receive antiviral therapy with nucleoside analogs according to the local guidance throughout the study 13. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and for 4 months after the last dose of study treatment 14. Life expectancy of 12 weeks or longer
Exclusion criteria
1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma 2. Prior cabozantinib treatment 3. Any systemic anti-cancer therapy administered after discontinuation of the first-line immune checkpoint inhibitor-based combination 4. Prior liver-directed locoregional therapy administered within 4 weeks before registration 5. Any liver-directed locoregional therapy performed after progression with the first-line immune checkpoint inhibitor-based combination, but palliative radiotherapy for symptomatic bone metastasis is allowed 6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months before registration 7. Presence of tumor thrombosis or invasion in inferior vena cava (IVC), a major arterial blood vessel (e.g., pulmonary artery or aorta) or heart 8. Subjects with HBV DNA \> 2000 IU/mL or detectable hepatitis C virus (HCV) RNA 9. Subjects refuse to provide tumor biopsy specimens within 4 weeks before registration 10. Concomitant anticoagulation, at therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, low molecular weight heparin (LMWH), thrombin or coagulation factor X (FXa) inhibitors. (Note: Low dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (≤ 1 mg/day), and low dose LMWH (e.g. 40 mg Enoxaparin) for prophylaxis of venous thromboembolism are permitted) 11. Subjects with uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: * Cardiovascular disorders including symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias * Uncontrolled hypertension defined as sustained systolic blood pressure (BP) \> 150 mm Hg, or diastolic BP \> 100 mm Hg despite optimal antihypertensive treatment * Stroke (including transient ischemic attack), myocardial infarction, or other ischemic event within 6 months * Thromboembolic event within 3 months. (Note: Subjects with thromboses of portal/hepatic vasculature attributed to underlying liver disease and/or liver tumour are eligible) * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation/bleeding: * Tumours invading the GI tract, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction * Abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess within 6 months 12. Major surgery within 2 months before registration. Complete healing from major surgery must have occurred 1 month before registration. Complete healing from minor surgery (e.g., simple excision, tooth extraction) must have occurred at least 7 days before registration 13. Clinically significant bleeding risk including the following within 3 months before registration: upper GI bleeding (including gastroesophageal varices bleeding), hematuria, hemoptysis of \>0.5 teaspoon (\>2.5 mL) of red blood, or other signs indicative of pulmonary hemorrhage, or history of other significant bleeding if not due to reversible external factors 14. Moderate or severe ascites (radiologically detected but clinically insignificant ascites without any diuretics or palliative paracentesis is allowed) 15. Corrected QT interval calculated by the Fridericia formula (QTcF) \> 500 ms within 4weeks before registration (Note: If the QTcF is \> 500 ms in first ECG, a total of 3 ECGs should be performed. If the average of these 3 consecutive results for QTcF is ≤ 500 ms, the subject meets eligibility) 16. Previously identified allergy or hypersensitivity to components of the study treatment formulations 17. Inability in swallowing tablets 18. Pregnant or lactating females 19. Diagnosis of another malignancy within 2 years before registration, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy 20. Other clinically significant disorders that are judged by investigators to be unsuitable for the clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free rate at 6 months | 30 months | The percentage of subjects remaining progression (per RECIST v1.1) -free at 6 months after initiation of study treament . |
| Treatment-emergent adverse event | 30 months | Incidence of treatment-emergent adverse events |
Countries
Taiwan
Contacts
Primary ContactBor-Rong Chen
Backup ContactYing-Chun Shen
Outcome results
None listed